DE69937580D1 - Agent zur induktion einer immunologischen toleranz - Google Patents

Agent zur induktion einer immunologischen toleranz

Info

Publication number
DE69937580D1
DE69937580D1 DE69937580T DE69937580T DE69937580D1 DE 69937580 D1 DE69937580 D1 DE 69937580D1 DE 69937580 T DE69937580 T DE 69937580T DE 69937580 T DE69937580 T DE 69937580T DE 69937580 D1 DE69937580 D1 DE 69937580D1
Authority
DE
Germany
Prior art keywords
inducing
agent
immunological tolerance
autoimmune diseases
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69937580T
Other languages
English (en)
Inventor
Ho-Youn Kim
Jong-Sang Park
Zae-Young Ryoo
Euiyoung Bae
Woo-Kyoung Lee
Chul-Soo Cho
Sung-Hwan Park
Wan-Uk Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IND ACADEMIC COOP
Original Assignee
IND ACADEMIC COOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IND ACADEMIC COOP filed Critical IND ACADEMIC COOP
Application granted granted Critical
Publication of DE69937580D1 publication Critical patent/DE69937580D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69937580T 1999-08-18 1999-08-18 Agent zur induktion einer immunologischen toleranz Expired - Lifetime DE69937580D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR1999/000460 WO2001012222A1 (en) 1999-08-18 1999-08-18 Immunological tolerance-induction agent

Publications (1)

Publication Number Publication Date
DE69937580D1 true DE69937580D1 (de) 2007-12-27

Family

ID=19570981

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69937580T Expired - Lifetime DE69937580D1 (de) 1999-08-18 1999-08-18 Agent zur induktion einer immunologischen toleranz

Country Status (6)

Country Link
EP (1) EP1212086B8 (de)
JP (1) JP3926626B2 (de)
AT (1) ATE378067T1 (de)
AU (1) AU5307899A (de)
DE (1) DE69937580D1 (de)
WO (1) WO2001012222A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230765A1 (en) * 2002-03-29 2003-10-13 Bayhill Therapeutics, Inc. Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
WO2004047778A1 (en) 2002-11-26 2004-06-10 Uc Tech Materials and methods for preventing and treating microbe-mediated epithelial disorders
JP2008297204A (ja) * 2007-05-29 2008-12-11 Masahiro Murakami ポリ乳酸混合物を含む肝繊維化の抑制又は改善剤
DE102007039446A1 (de) 2007-08-21 2009-02-26 Volkswagen Ag Verfahren zum Anzeigen von Informationen in einem Kraftfahrzeug mit veränderbarem Maßstab und Anzeigeeinrichtung
EP2254588B1 (de) * 2008-03-14 2017-10-11 Cel-Sci Corporation Verfahren zur herstellung und zusammensetzung von peptidkonstrukten für die behandlung von rheumatoider arthritis
CA2770570A1 (en) * 2009-08-12 2011-02-17 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
WO2012065153A2 (en) 2010-11-12 2012-05-18 Daniel Getts Modified immune-modulating particles
WO2012162564A1 (en) 2011-05-25 2012-11-29 Cel-Sci Corporation Method for inducing an immune response and formulations thereof
KR20220166879A (ko) 2012-06-21 2022-12-19 노쓰웨스턴유니버시티 펩티드 접합된 입자
AU2014243758B2 (en) 2013-03-13 2019-02-07 Oncour Pharma, Inc. Immune-modifying particles for the treatment of inflammation
MX2016001931A (es) 2013-08-13 2016-09-07 Univ Northwestern Particulas conjugadas con peptidos.
CN111109198B (zh) * 2019-03-29 2021-08-20 成都华西海圻医药科技有限公司 一种葡萄膜炎动物模型构建方法
US20220226499A1 (en) * 2019-05-16 2022-07-21 Arizona Board Of Regents On Behalf Of Arizona State University Metabolite Delivery for Modulating Metabolic Pathways of Cells
WO2021050812A1 (en) * 2019-09-12 2021-03-18 Arizona Board Of Regents On Behalf Of Arizona State University Metabolic reprogramming of immune cells for the treatment or prevention of diseases and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0701569B1 (de) * 1992-12-03 2008-11-12 The Regents Of The University Of California Verbesserte reagentien und methoden zur diagnose und behandlung von diabetes und stiff man syndrome
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
EP1009386B1 (de) * 1997-08-29 2005-08-31 Corixa Corporation Schnellfreisetzende enkapsulierte bioaktive wirkstoffe zur induzierung einer immunantwort und verwendung derselben
AU2566799A (en) * 1998-01-27 1999-08-09 Jane Pei-Fan Bai Chemical derivatives of autoantigens and autoimmune-suppressive peptides and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
WO2001012222A1 (en) 2001-02-22
JP3926626B2 (ja) 2007-06-06
EP1212086B8 (de) 2008-01-02
ATE378067T1 (de) 2007-11-15
EP1212086B1 (de) 2007-11-14
AU5307899A (en) 2001-03-13
EP1212086A1 (de) 2002-06-12
JP2003507340A (ja) 2003-02-25

Similar Documents

Publication Publication Date Title
ATE378067T1 (de) Agent zur induktion einer immunologischen toleranz
WO2001085154A3 (en) Method of treating immune pathologies with low dose estrogen
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
NO963280D0 (no) Anvendelse av anti-TNF antistoffer som legemidler i behandling av sykdommer som involverer forhöyede interleukin-6 serumnivåer
BR9814393A (pt) Micropartìculas e uso terapêutico ou diagnóstico delas
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
DE69605184D1 (de) Verabreichung einer substanz in den mund
DE69936393D1 (de) Behandlung akuter gesundheitsstörungen durch die sublingual verabreichung einer pharmazeutischen zusammensetzung
TR199900656T2 (xx) �ndanonlar ile 262 ve 20S proteazomun engellenmesi.
EE9800435A (et) H+, K+-ATPaasi inhibiitorite manustamise reziim
SE9602931D0 (sv) New medicinal use
IT1319275B1 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo.
BG106226A (en) A blocking monoclinal antibody to vla-1 and its use for the treatment of inflammatory disorders
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
NO20030985D0 (no) Behandling av betennelsestilstander
NZ284914A (en) use of anti-arthritogenic peptide antibodies, nonadsorbable antibiotic or benign bacteria to treat rheumatoid arthritis by enteral administration
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
Tse et al. Chronic bullous dermatosis of childhood: Differentiation from other autoimmune blistering diseases in children
DE69831416D1 (de) Chinolin-harnstoff-derivate zur behandlung von entzugssyndrom und durch entzugssyndrom verursachten gehirnschaden
SE9700617D0 (sv) New composition
IL163431A (en) 1 - phenyl - 2 - heteroaryl - substituted benzimidazole derivatives and the use thereof for producing drugs used in the treatment of immunological diseases
MX9503625A (es) Metodo para reducir el daño por radicales libres en celulas de mamiferos vivos.
WO2002026258A3 (en) Treatment of immune-mediated diseases by oral administration of plasma fractions
TR200102262T2 (tr) Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem.
UA42351A (uk) Спосіб лікування туберкульозу

Legal Events

Date Code Title Description
8332 No legal effect for de